Published • loading... • Updated
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in ...
Summary by Hastings Tribune
4 Articles
4 Articles
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated...
·Manila, Philippines (the)
Read Full Article
Hastings TribuneReposted by 
The Caledonian Record
The Caledonian RecordAscentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in ...
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical…
·Nebraska, United States
Read Full Article
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
